Similarly, changes in CgA levels during treatment—particularly with somatostatin analogs or peptide receptor radionuclide therapy (PRRT)—have been proposed as surrogate markers of treatment response, but these remain unreliable and heavily dependent on tumor differentiation and secretory profile [68]. Here, CGA is linked to neoplasm.